环码生物 is a biopharmaceutical company focused on developing nucleic acid drugs based on a unique circular RNA technology platform. The company says it possesses globally leading circular RNA design, optimization, preparation technologies and related patents, and was founded by scientists with long experience in RNA research. Scientific founder Wang Zefeng’s team first reported in 2014 that circular RNAs can be translated in human cells, opening applications of circular RNA as a new mRNA therapy. The team includes domestic and international senior biopharma professionals supporting pipeline R&D, process scale-up, quality control and IP strategy. The company plans to use new funds to完善 the circular RNA platform, advance its pipeline, build a Shanghai R&D center and continue recruiting global talent. Management emphasizes circular RNA advantages versus linear mRNA in stability, expression and immunogenicity and intends to push circular RNA therapeutics toward market.

Total raised

$20M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2022